PPCB (Propanc Biopharma) Earnings per share for the last four quarters

Public company logo of Propanc Biopharma Inc. (PPCB)

Propanc Biopharma Inc (PPCB) is based on pancreatic enzyme patents and synergy with European and Australian universities. The YoY EPS growth rates over 12 months on this GURU.Markets chart confirm this trajectory, where the 99.70 metric determines this level. The company is currently in the R&D phase, developing proenzymes to combat solid tumor metastases.

PPCB Propanc Biopharma Earnings per share for the last twelve months (11/23/2025 - 11/14/2026)

Propanc Biopharma, Inc. - analytical breakdowns and key metrics (PPCB)

- current price and projected stock value:
Price Performance Chart Propanc Biopharma Inc|PPCB - Consensus Target
- business market valuation indicators:
Market Value Propanc Biopharma, Inc.|PPCB - Enterprise Value
- business book valuation details:
Book Value per Share Propanc Biopharma|PPCB - Company Book Value|Market Value to Book Value propanc.com|PPCB - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio Propanc Biopharma Inc|PPCB - Long-Term Debt to Capital|Current Liabilities to Capital Propanc Biopharma Inc|PPCB - Company Total Debt|Debt to Book Capital Propanc Biopharma, Inc.|PPCB - Company Long-Term Debts|Short-Term Debt Propanc Biopharma|Immediate Liquidity Ratio propanc.com
- earnings and multiples data:
PPCB - Net Income|Expected Net Income Propanc Biopharma Inc|PPCB - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Propanc Biopharma Inc|PPCB - PEG Multiple|Business Value to Operating Income Before Depreciation Propanc Biopharma, Inc.|PPCB - Operating profit EBITDA|Net earnings per one share for the last twelve months Propanc Biopharma|PPCB - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months propanc.com|PPCB - Earnings growth in current year|Earnings growth forecast for next year Propanc Biopharma Inc
- revenue and sales details:
PPCB - Company Revenue|Company Expected Revenue Propanc Biopharma Inc|PPCB - Market Cap to Revenue|Market Cap to Future Revenue Ratio Propanc Biopharma, Inc.
Fundamental valuation:Propanc Biopharma (PPCB)
Signature product of Propanc Biopharma Inc.

Propanc Biopharma Inc. reduces risks by diversifying its pipeline for combating solid tumor metastases, yet the actual effectiveness of this strategy is reflected in the growth rate of rolling earnings per share. This indicator measures the speed of business capitalization, neutralizing quarterly reporting gaps to assess the actual growth of shareholder value. Analyzing the year-over-year (12-month) EPS trend allows for the timely identification of trend reversals and the avoidance of losses.

Competitor analysis for Propanc Biopharma Inc

Earnings per share for the trailing year GMAB (genmab.com)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) IDEAYA Corp|Earnings per share for the last twelve months Enliven Therapeutics (ELVN)|ORIC (oricpharma.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics, Inc.)|Net earnings per share for the trailing year Nurix Therapeutics Inc|Tyra Bio - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem Corp|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (Immuneering) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Therapeutics Inc CCCC|Net earnings per share (EPS TTM) BDTX|Repare Therapeutics Inc - Earnings per share for the last 12 months|PMV Pharmaceuticals - Net earnings per share for the last 12 months|Earnings per share for the trailing year KPTI|BGMS: Net earnings per share for the last 12 months|Aadi Bioscience - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corporation - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months springworkstx.com SWTX